Seres therapeutics publishes positive ser-287 phase 1b ulcerative colitis study results in journal gastroenterology

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) today announced the publication of data analyses from the company's phase 1b trial of ser-287 in patients with active mild-to-moderate ulcerative colitis (uc), most of whom were failing current therapies. the study results demonstrated that ser-287 administration was associated with positive impacts on clinical remission, endoscopic improvement, modulation of the gastrointestinal microbiome, and a favorable tolerability
MCRB Ratings Summary
MCRB Quant Ranking